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Abstract
Background: Mutations in the mitochondrial DNA (mtDNA) have been associated with aminoglycoside-induced
and nonsyndromic deafness in different populations. In the present study, we investigated the contribution of
mutations in mitochondrial genes to the etiology of hearing loss in a Brazilian sample.
Methods: Using mass spectrometry genotyping technology, combined with direct sequencing, 50 alterations
previously described in 14 mitochondrial genes were screened in 152 patients with sensorineural hearing loss and
in104 normal hearing controls.
Results: Fifteen known mitochondrial alterations were detected (G709A, A735G, A827G, G988A, A1555G, T4363C,
T5628C, T5655C, G5821A, C7462T, G8363A, T10454C, G12236A, T1291C, G15927A). Pathogenic mutations in MT-RNR1
and MT-TK genes were detected in 3 % (5/152) of the patients with hearing loss.
Conclusions: This study contributed to show the spectrum of mitochondrial variants in Brazilian patients with
hearing loss. Frequency of A1555G was relatively high (2.6 %), indicating that this mutation is an important cause of
hearing loss in our population. This work reports for the first time the investigation and the detection of the
tRNALys G8363A mutation in Brazilian patients with maternally inherited sensorineural hearing loss.
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Background
Hearing loss (HL) is the most common sensory disorder,
affecting one child in every 500 to 1000 at birth [1].
Genetic causes are estimated to represent 50–70 % of
congenital deafness cases. Although most of hereditary
HL cases are caused by mutations in nuclear genes,
alterations in mitochondrial genes have been found in at
least 5 % of patients with post-lingual nonsyndromic
hearing loss [2].
Mutations in the mitochondrial DNA (mtDNA) can
have structural and functional effects, including
changes in RNA structure, reductions in the levels of
mRNA or tRNA, and modification of tRNA. The
deleterious effect of mtDNA mutations on energy me-
tabolism appears to be the central pathogenic factor,
although other important aspects of mitochondrial
function may also play a role in disease pathogenesis,
such as the generation of reactive oxygen species
(ROS) and the regulation of programmed cell death,
or apoptosis [3].
Many mitochondrial mutations have been associated
with hearing loss, but the full range of phenotypic ex-
pression has not been well characterized, mainly due to
the lack of consensus on audiological criteria and the
low frequency of some mutations present in only a small
number of cases. Further studies are necessary to estab-
lish the importance of the detected mutations for the
diagnosis of hearing loss.
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The most frequent mitochondrial mutations known to
cause HL are the A1555G and C1494T alterations, which
have been associated with aminoglycoside-induced and
nonsyndromic deafness in families from many different
ethnic backgrounds [4, 5]. Many other sequence variants
have been proposed to be associated with hearing loss;
however, most of them are not definitively related to hear-
ing loss, because they have been found in normal hearing
individuals and/or because of their mtDNA phylogeny [6].
At present, little is known about the incidence of mtDNA
mutations in Brazilian patients. Previously published data
have mainly focused on the A1555G mutation [7, 8] and
there are no studies including a large number of deafness-
associated mtDNA mutations.
In the present work, we investigated 50 alterations in 14
mitochondrial genes in order to estimate the frequency
and involvement of known and putative mutations in
Brazilian patients with sensorineural hearing loss. We also
investigated the potential of the single nucleotide poly-
morphism (SNP) genotyping technology called iPLEX
Gold MALDI-TOF MS (matrix-assisted laser desorption/
ionization - time of fight mass spectrometry), developed
by Sequenom Inc. (San Diego, CA), for the simultaneous
analysis of mitochondrial alterations. This is the first study
to undertake a systematic screening of Brazilian patients
for mtDNA variations using MALDI-TOF MS.
Methods
Casuistics
We evaluated 152 unrelated patients of both genders (82
females and 70 males) with moderate to profound sen-
sorineural HL. Samples from these individuals had been
referred to the Human Molecular Genetics Laboratory
of the Center for Molecular Biology and Molecular En-
gineering (CBMEG) at the University of Campinas
(UNICAMP) by different organizations, in order to de-
termine the etiology of HL. This work was a retrospect-
ive study using collected DNA samples from 2000 to
2013. Most of the patients included in the casuistic of
this study were adults or young adults with progressive
hearing loss with an age at diagnosis varying from child-
hood to early adulthood. Information of family history
was scarcely available and not systematically for all
patients.
In addition, 104 samples from normal hearing individ-
uals were used as controls. The study was approved by
the Research Ethics Committee of the Faculty of Medical
Sciences of UNICAMP (Number 396/2006), and in-
formed consent was obtained from all participants.
DNA extraction
Genomic DNA was obtained from peripheral blood leuko-
cytes using standard phenol-chloroform extraction. The
molecular analysis was performed at CBMEG (UNICAMP).
The purities and concentrations of the samples were deter-
mined using a NanoDrop® 8000 spectrophotometer
(Thermo Scientific) and a Qubit® 2.0 fluorometer (Invitro-
gen), respectively. All the samples showed A260/280 ratios
between 1.8 and 2.0. Genomic DNA samples were diluted
to obtain a final concentration of 5 ng/μL.
Mutation analysis of the DFNB1 locus
Mutations in the DFNB1 locus, involving the GJB2 and
GJB6 genes, are the most common cause of autosomal re-
cessive nonsyndromic hearing loss (ARNSHL). All the sam-
ples were therefore previously tested for the presence of
mutations in the coding region of GJB2 and for the intronic
mutation IVS1 + 1G >A, using PCR, followed by direct se-
quencing using ABI BigDye Terminator and analysis with
an ABI PRISM® 3700 DNA sequencer (Applied Biosystems)
[9]. A multiplex PCR methodology was used to detect
del(GJB6-D13S1830) and del(GJB6-D13S1854), according
to the procedures reported previously [10, 11]. Patients
with HL due to mutations in the DFNB1 locus were ruled
out for subsequent analyses.
Mutation analysis of the mtDNA
A total of 50 mitochondrial alterations related to non-
syndromic HL, described in the Human Mitochondrial
Genome Database (MITOMAP) [12], were screened
using the iPLEX Gold/MALDI-TOF MS technology
(Sequenom Inc., San Diego, CA). These alterations are
spread in a total of 14 genes as listed in Table 1.
All the results were validated by direct sequencing,
using the same primers used in iPLEX Gold locus-
specific PCR reactions. DNA sequencing was performed
with the ABI BigDye™ Terminator v3.1 Cycle Sequencing
Kit on an ABI PRISM® 3700 DNA Analyzer (Applied
Biosystem), according to manufacturer’s instructions.
The Chromas Lite v2.0 (Technelysium Pty Ltd) and CLC
Sequence Viewer v6 (CLC bio) free softwares were used
to analyze sequencing data.
iPLEX Gold/MALDI-TOF MS
Based on the sequence data available from MITOMAP
[12], MassARRAY Assay Designer software (Sequenom
Inc., San Diego, USA) was used to design PCR and sin-
gle base extension (SBE) primers for all 50 mtDNA vari-
ants investigated. The iPLEX Gold technology consists
of an initial locus-specific PCR reaction, followed by SBE
using mass-modified dideoxynucleotide terminators of
an oligonucleotide primer that anneals immediately up-
stream of the polymorphic site of interest. Matrix-
assisted laser desorption/ionization time-of-flight mass
spectrometry (MALDI-TOF MS) is used to identify the
corresponding allele according to the mass of the ex-
tended primer.
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The optimal amplicon size was set to 80–120 bp. A
10-mer tag (5’-ACGTTGGATG-3’) was added to the 5’
end of each PCR primer to avoid confusion in the mass
spectrum, and SBE primers were 5’ tailed with nonho-
mologous sequences of varying lengths to create large
enough mass differences between the different SBE
products to be detected by MALDI-TOF MS. In order
to avoid interaction among the primers of the 83-plex
(83 reactions), the MassARRAY Assay Designer software
divided the PCR amplification and the SBE into 5 multi-
plex reactions.
The whole process was performed according to the
manufacturer’s instructions for the multiplex reactions,
including the PCR amplification, the shrimp alkaline
phosphatase (SAP) treatment, and the primer extension
reactions using the iPLEX Gold assay. The reaction
products were then dispensed onto a 384-SpectroCHIP
using the MassARRAY Nanodispenser, and were ana-
lyzed on the MassARRAY platform. Mass signals for the
different alleles were captured with high accuracy by
MALDI-TOF MS. Typer software v4.0 (Sequenom Inc.,
San Diego, CA) was used to process the raw data ob-
tained from the assays.
Results
The iPLEXGold/MALDI-TOF MS method was used to
screen 50 mtDNA mutations associated with hearing
loss. A total of 256 samples obtained from 152 patients
with sensorineural HL and 104 normal hearing controls
were analyzed. Fifteen different mtDNA alterations were
detected: G709A, A735G, A827G, A988G, A1555G,
T4363C, T5628C, T5655C, G5821A, C7462T, G8363A,
T10454C, G12236A, T1291C, G15927A (Table 2). Based
on the MITOMAP database, status was considered
‘Confirmed’ if at least two or more independent studies
have reported the pathogenicity of a specific mutation.
Ambiguous substitutions were categorized as ‘Unclear’
or ‘Conflicting’. ‘Reported’ status indicates that one or
more reports have considered the mutation as possibly
pathogenic (Table 2). Only 3 % (5/152) of the patients
had ‘Confirmed’ mutations (4/A1555G and 1/G8363A).
Two alterations (C7462T and A735G) were only found
in the control group, seven only in patients with HL and
six were found in both patients and control group. The
T4363C alteration was detected in all the individuals an-
alyzed (Table 3). All the results were confirmed by direct
sequencing and showed a 100 % match for it.
Discussion
Fifteen known mitochondrial mutations were detected in
this study. Seven of them, A988G, A1555G, T5628C,
G8363A, T10454C, G12236A and G15927A, were found
only in the patients with HL, supporting the pathogenicity
of these mutations. The A1555G (4/152) classified as
Table 1 mtDNA alterations analyzed by MALDI-TOF mass
spectrometry
Gene Alteration RNA
MT-TF A622G tRNAPhe
A636G tRNAPhe
T642C tRNAPhe
MT-RNR1 T669C 12S rRNA
G709A 12S rRNA
A735G 12S rRNA
A745G 12S rRNA
A792G 12S rRNA
A801G 12S rRNA
A827G 12S rRNA
A839G 12S rRNA
A856G 12S rRNA
G988A 12S rRNA
T990C 12S rRNA
T1005C 12S rRNA
A1027G 12S rRNA
A1116G 12S rRNA
T1180G 12S rRNA
C1192A 12S rRNA
C1226G 12S rRNA
T1291C 12S rRNA
C1310T 12S rRNA
A1331G 12S rRNA
A1374G 12S rRNA
T1452C 12S rRNA
A1453G 12S rRNA
C1494T 12S rRNA
C1537T 12S rRNA
A1555G 12S rRNA
MT-TI A4316G tRNAIle
MT-TQ T4336C tRNAGln
T4363C tRNAGln
MT-TW G5540A tRNATrp
A5568G tRNATrp
MT-TA T5587C tRNAAla
T5628C tRNAAla
T5655C tRNAAla
MT-TC T5802C tRNACys
G5821A tRNACys
MT-TS1 A7445C tRNASer (UCN)
A7456G tRNASer (UCN)
C7462T tRNASer (UCN)
MT-TK G8363A tRNALys
MT-TR T10454C tRNAArg
MT-TH G12183A tRNAHis
MT-TS2 C12224T tRNASer (AGY)
G12236A tRNASer (AGY)
MT-TE A14693G tRNAGlu
MT-TT T15908C tRNAThr
G15927A tRNAThr
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Table 2 Summary of alterations identified only in patients with sensorineural HL
Patient Alteration Gene Haplogroup Gender Hetero/Homoplasmy Statusa
Mit05 A827G MT-RNR1 L3 – R M Homo Conflicting
Mit12 A827G MT-RNR1 L3 – R M Homo Conflicting
Mit13 A827G MT-RNR1 L3 - R F Homo Conflicting
Mit15 G8363A - G15927A MT-TK
MT-TT
L3 - X - J M Homo Confirmed
Possible helper
Mit17 A1555G MT-RNR1 L3 - D M Homo Confirmed
Mit18 A1555G MT-RNR1 L3 - D M Homo Confirmed
Mit19 A827G MT-RNR1 L3 - R M Homo Conflicting
Mit21 A827G MT-RNR1 L3 - R F Homo Conflicting
Mit24 G709A MT-RNR1 L3 - R - T F Homo Reported
Mit25 T5655C MT-TA L1/L2 M Hetero Reported
Mit27 A827G MT-RNR1 L3 M Homo Conflicting
Mit29 A827G MT-RNR1 L3 - R M Homo Conflicting
Mit32 A827G MT-RNR1 L3 - R F Homo Conflicting
Mit33 A1555G MT-RNR1 L1/L2 M Homo Confirmed
Mit34 G709A MT-RNR1 L3 - R - T F Homo Reported
Mit36 G709A MT-RNR1 L3 - R - T F Hetero Reported
Mit43 G709A MT-RNR1 L1/L2 M Hetero Reported
Mit47 A1555G MT-RNR1 L3 - R - H F Homo Confirmed
Mit48 A1555G MT-RNR1 L1/L2 M Homo Confirmed
Mit49 A827G MT-RNR1 L3 - R M Homo Conflicting
Mit54 G709A MT-RNR1 L3 - R - T M Hetero Reported
Mit57 A827G MT-RNR1 L3 - R M Homo Conflicting
Mit59 A827G MT-RNR1 L3 - R F Homo Conflicting
Mit63 G5821A MT-TC L1/L2 M Homo Reported
Mit74 A827G MT-RNR1 L3 - R - T F Homo Conflicting
Mit77 G12236A MT-TS2 L1/L2 F Homo Reported
Mit85 G709A MT-RNR1 L3 - R M Homo Reported
Mit86 A827G MT-RNR1 L3 M Homo Conflicting
Mit91 G709A MT-RNR1 L3 F Homo Reported
Mit94 A827G MT-RNR1 L3 - R F Homo Conflicting
Mit96 G709A MT-RNR1 L3 - R M Homo Reported
Mit97 A827G MT-RNR1 L3 - R M Homo Conflicting
Mit98 T5655C MT-TA L1/L2 F Homo Reported
Mit99 A827G MT-RNR1 L3 - R M Homo Conflicting
Mit100 T5655C MT-TA L3 F Hetero Reported
Mit102 G709A MT-RNR1 L3 - R - T F Homo Reported
Mit108 T5628C-G988A MT-TA
MT-RNR1
L3 F Homo Reported
Reported
Mit117 G709A MT-RNR1 L3 M Homo Reported
Mit118 T1291C MT-RNR1 L1/L2 F Homo Unclear
Mit129 A827G MT-RNR1 R - T M Homo Conflicting
Mit130 G709A MT-RNR1 L3 - R F Hetero Reported
Mit133 T10454C MT-TR L1/L2 M Homo Reported
Mit135 T5655C MT-TA L1/L2 M Homo Reported
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‘Confirmed’ by MITOMAP database was found in the pa-
tients with moderate to profound sensorineural HL. The
A1555G mutation in the highly conserved decoding site of
the mitochondrial 12S rRNA alters the secondary structure,
so that it resembles the corresponding region of bacterial
16S rRNA, increasing the risk of hearing impairment due
to aminoglycosides exposure [13]. Frequency of A1555G
was relatively high (2.6 %) indicating that this alteration
should be included in the mutation group routinely investi-
gated in Brazilian patients with sensorineural HL [14].
Aminoglycoside-induced and nonsyndromic deafness has
been shown to have a genetic susceptibility and the patho-
genic mitochondrial 12S rRNA A1555G mutation was
identified as the primary factor underlying the hearing loss,
particularly in countries where aminoglycoside antibiotics
are commonly used even for minor infections [15]. How-
ever, the A1555G mutation has also been reported in
hearing-impaired patients with no history of exposure to
aminoglycoside antibiotics, suggesting that in some carriers
of this mutation aminoglycoside exposure is not necessary
for the occurrence of HL, and additional environmental
and/or genetic risk factors may influence the penetrance
and expressivity [16].
In the present study, none of the patients with HL car-
rying the A1555G mutation reported the use of
aminoglycosides.
One patient (Mit15) carrying the G15927A mutation in
the tRNALys gene also presented the known pathogenic
G8363A mutation in the tRNALys gene, apparently in
homoplasmy after MALDI-TOF MS and sequencing. The
G8363A mutation has been reported for the first time in
two unrelated families, causing encephalomyopathy, sen-
sorineural hearing loss and hypertrophic cardiomyopathy
[17]. Previous studies have shown that the same mutation
can determine a large phenotypical variability ranging
from MERRF-like syndrome, maternally inherited cardio-
myopathy, deafness, autism, or Leigh syndrome [18–20].
The G8363A abolishes a highly conserved pairing in the
aminoacyl stem of the tRNALys altering the overall sec-
ondary structure of the molecule and consequently im-
pairs the activity of peptidyl-tRNA hydrolase, which is
critical for protein translation [21]. On the other hand, the
G15927A mutation abolishes the conserved base pairing
28C-42G on the anticodon stem of tRNAThr and conse-
quently alters the metabolism of this tRNA. The G15927A
have been implicated in enhancing the penetrance and
expressivity of the deafness-associated 12S rRNA A1555G
mutation [22, 23]. However, the association of the
G15927A mutation with coronary heart disease is contro-
versial [24].
The patient Mit15 carrying G8363A and G15927A mu-
tations was a Brazilian 26-year-old man who had bilateral
progressive sensorineural HL starting at around 11 years
of age, and subsequently underwent cochlear implantation
at 22 years old. To date, no other clinical signs or symp-
toms were detected. Family history was remarkable for
two brothers who presented similar phenotype and carry-
ing the same mutations in homoplasmy. Curiously, the
mother presented G15927A in homoplasmy but G8363A
in heteroplasmy and she has normal audiological exami-
nations. The G8363A mutation is being reported for the
first time in a Brazilian patient with sensorineural HL.
Nonetheless, more studies are necessary to determine the
frequency of this mtDNA mutation in our country.
Table 2 Summary of alterations identified only in patients with sensorineural HL (Continued)
Mit137 A827G MT-RNR1 L3 - R F Homo Conflicting
Mit140 G709A MT-RNR1 L3 M Homo Reported
Mit144 A827G MT-RNR1 L3 - R M Homo Conflicting
Mit145 A827G MT-RNR1 L3 - R M Homo Conflicting
Mit149 G709A MT-RNR1 L3 M Homo Reported
Mit151 A827G MT-RNR1 L3 – T M Homo Reported
aBased on the MITOMAP database; ‘Reported’ status indicates that one or more reports have considered the mutation as possibly pathologic. ‘Confirmed’ (bold)
indicates that two or more independent studies had reported about the pathogenicity of specific mutation
Table 3 Frequency of mitochondrial DNA alterations identified
in patients with sensorineural HL and normal hearing individuals
Alteration Patients Normal controls
A1555G. 4/152 (2.6 %) 0
A827G. 20/152 (13.2 %) 9/104 (8.6 %)
G709A. 14/152 (9.2 %) 13/104 (12.5 %)
G8363A. 1/152 (0.7 %) 0
G15927A. 1/152 (0.7 %) 0
G12236A. 1/152 (0.7 %) 0
T10454C. 1/152 (0.7 %) 0
T5628C. 1/152 (0.7 %) 0
A988G. 1/152 (0.7 %) 0
G5821A. 1/152 (0.7 %) 2/104 (1.9 %)
T5655C 4/152 (2.6 %) 4/104 (3.8 %)
T1291C 1/152 (0,7 %) 6/104 (5,8 %)
C7462T 0 1/104 (1 %)
A735G 0 1/104 (1 %)
T4363C 152 (100 %) 104 (100 %)
Alves et al. BMC Medical Genetics  (2016) 17:41 Page 5 of 7
The alterations 12S rRNA G988A, tRNAAla T5628C,
tRNAArg T10454C, tRNASer(AGY) G12236A were detected
in four patients with sensorineural HL. These mtDNA
mutations can contribute to the phenotype because (1)
they affect highly conserved nucleotides in mitochondrial
genes (conservation index >50 %), (2) they were found in
maternal inheritance (some were also found as sporadic
cases), (3) None of these mutations were found in normal
hearing controls and (4) they lead to structural alterations
and affect the function of rRNA or may impair mitochon-
drial translation by reducing the availability of functional
mt-tRNAs [25–28]. Nevertheless, among these mutations
only G12236A have been considered deleterious [26, 29].
The G988A, T5628C and T10454C mutations were re-
ported as a possible risk factor for deafness or modulating
factors of the phenotypic expression of pathogenic muta-
tions, indicating that these alterations themselves are not
sufficient to cause clinical symptoms.
The A827G mutation was the most frequent in pa-
tients with HL, being present in 20 out of 152 (13 %). In
the normal controls, the frequency was 9 out of 104
(8.6 %). A significant difference in the proportion of in-
dividuals with the A827G mutation among the patients
with HL (13 %) and normal hearing controls (8.6 %) was
observed. Similar results were found in other studies in
different populations [30–32]. The A827G mutation has
been implicated in aminoglycoside ototoxicity and non-
syndromic HL. Xing et al. (2006) [33] studied two unre-
lated Chinese families with HLs, and found that this
mutation was present in all the maternal relatives, while
not all mutation carriers were affected. The A827G mu-
tation is located at the highly conserved A-site of the
12S rRNA gene. It is possible that the alteration of the
tertiary or quaternary structures of this rRNA by the
A827G mutation may lead to mitochondrial dysfunction,
thereby playing a role in the pathogenesis of hearing loss
and aminoglycoside hypersensitivity. However, the in-
complete penetrance indicates that the A827G mutation
alone is not sufficient to produce clinical phenotype, re-
quiring the involvement of modifying factors including
aminoglycosides, mitochondrial haplotypes or nuclear
modifier genes [34–36]. On the other hand, the contri-
bution of this variant to HL remains controversial, given
its high frequency in the normal population [32].
The two most important mitochondrial genes associated
with nonsyndromic HL are the MT-RNR1and MT-TS1.
However, genotyping of mutations using mass spectrom-
etry resulted in discernment of alterations in six other
genes (MT-TK, MT-TT, MT-TA, MT-TS2, MT-TC, and
MT-TR). The iPLEX Gold/MALDI-TOF MS methodology
enables automated large-scale mutation screening, provid-
ing accuracy and high-throughput. The data are easy to
interpret, due to the use of a well-established protocol,
although the results should be confirmed by other
methods. The main drawbacks of the iPLEX assay are the
requirement for specific equipment and the cost of the
MassARRAY instrumentation. Nonetheless, the technique
offers a high level of flexibility and a low cost per geno-
type. The use of MALDI-TOF MS could be especially ap-
pealing for laboratories with medium to high-throughput
activities.
Due to great genetic heterogeneity, the molecular diag-
nosis of different types of hereditary hearing loss has
been challenging. The spectrum of molecular tests avail-
able is growing significantly but it is also critical to note
that they are not available for all deafness genes. There-
fore, it is important to know the most frequent muta-
tions in the population of interest to the elaboration of
specific high-throughput panels containing only the
commonest mutations, in order to reduce costs and
allow the rapid screening of large number of patients in
routine tests. MtDNA analysis can contribute to the
diagnosis of syndromic HL before the onset of clinical
symptoms; can distinguish individuals with mitochon-
drial mutations who are at risk for HL when treated with
aminoglycosides; and allow for more accurate genetic
counseling.
Conclusion
Systematic analysis of mtDNA mutations by iPLEX Gold/
MALDI-TOF MS methodology in Brazilian patients with
sensorineural HL contributed for provide the range of
main alterations of mitochondrial genes in Brazilian pa-
tients with HL. Fifteen known mitochondrial mutations
were detected in this study. At least two of them (A1555G
and G8363A) should be included in the screening of gen-
etic alterations related to HL. The rare G8363A mutation
in mtDNA tRNALys gene was reported for the first time in
a Brazilian patient with sensorineural HL.
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